{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:15:03Z","timestamp":1749701703805,"version":"3.41.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,11]]},"DOI":"10.7759\/cureus.85798","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T22:06:07Z","timestamp":1749679567000},"source":"Crossref","is-referenced-by-count":0,"title":["Robotic Stereotactic Body Radiation Therapy for High-Risk Prostate Cancer: The Georgetown University Experience"],"prefix":"10.7759","author":[{"given":"Vaibhav","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zach","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padraig Brennan","family":"Pilkington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marielle","family":"Fis Loperena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malika","family":"Danner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan L","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Carrasquilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suy","family":"Simeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.08.014","article-title":"Tumor control probability modeling and systematic review of the literature of stereotactic body radiation therapy for prostate cancer","volume":"110","author":"Royce TJ","year":"2021","unstructured":"Royce TJ, Mavroidis P, Wang K, et al.. Tumor control probability modeling and systematic review of the literature of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2021, 110:227-36. 10.1016\/j.ijrobp.2020.08.014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints","volume":"102","author":"Meier RM","year":"2018","unstructured":"Meier RM, Bloch DA, Cotrutz C, et al.. Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys. 2018, 102:296-303. 10.1016\/j.ijrobp.2018.05.040","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan AU","year":"2019","unstructured":"Kishan AU, Dang A, Katz AJ, et al.. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019, 2:188006. 10.1001\/jamanetworkopen.2018.8006","journal-title":"JAMA Netw Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As N","year":"2024","unstructured":"van As N, Griffin C, Tree A, et al.. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med. 2024, 391:1413-25. 10.1056\/NEJMoa2403365","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"10196","author":"Widmark A","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, et al.. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019, 10196:385-95. 10.1016\/S0140-6736(19)31131-6","journal-title":"Lancet"},{"key":"ref6","unstructured":"Acute lymphoblastic leukemia. (2025). Accessed. March 10, 2025: https:\/\/www.nccn.org\/guidelines\/guidelines-detail."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.11.044","article-title":"Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer","volume":"70","author":"Zelefsky MJ","year":"2008","unstructured":"Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008, 70:1124-9. 10.1016\/j.ijrobp.2007.11.044","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109632","article-title":"Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients","volume":"183","author":"Miszczyk M","year":"2023","unstructured":"Miszczyk M, Magrowski \u0141, Krzysztofiak T, et al.. Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients. Radiother Oncol. 2023, 183:109632. 10.1016\/j.radonc.2023.109632","journal-title":"Radiother Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"Ascende-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda S","year":"2017","unstructured":"Rodda S, Tyldesley S, Morris WJ, et al.. Ascende-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017, 98:286-95. 10.1016\/j.ijrobp.2017.01.008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00005","article-title":"Intensity-modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: a report on 3-year toxicity","volume":"7","author":"Paydar I","year":"2017","unstructured":"Paydar I, Pepin A, Cyr RA, et al.. Intensity-modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: a report on 3-year toxicity. Front Oncol. 2017, 7:5. 10.3389\/fonc.2017.00005","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.12.034","article-title":"Stereotactic body radiation therapy and high-dose-rate brachytherapy boost in combination with intensity modulated radiation therapy for localized prostate cancer: a single-institution propensity score matched analysis","volume":"110","author":"Chen WC","year":"2021","unstructured":"Chen WC, Li Y, Lazar A, et al.. Stereotactic body radiation therapy and high-dose-rate brachytherapy boost in combination with intensity modulated radiation therapy for localized prostate cancer: a single-institution propensity score matched analysis. Int J Radiat Oncol Biol Phys. 2021, 110:429-37. 10.1016\/j.ijrobp.2020.12.034","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.07.1752","article-title":"Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer","volume":"78","author":"Hossain S","year":"2010","unstructured":"Hossain S, Xia P, Huang K, et al.. Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010, 78:58-63. 10.1016\/j.ijrobp.2009.07.1752","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience","volume":"8","author":"Chen LN","year":"2013","unstructured":"Chen LN, Suy S, Uhm S, et al.. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013, 8:58. 10.1186\/1748-717X-8-58","journal-title":"Radiat Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.04.051","article-title":"Intrafractional motion of the prostate during hypofractionated radiotherapy","volume":"72","author":"Xie Y","year":"2008","unstructured":"Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2008, 72:236-46. 10.1016\/j.ijrobp.2008.04.051","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.01.014","article-title":"Dosimetric comparison of CyberKnife and conventional linac prostate stereotactic body radiation therapy plans: analysis of the pace-B study","author":"Ratnakumaran R","year":"2025","unstructured":"Ratnakumaran R, Sasitharan A, Khan A, et al.. Dosimetric comparison of CyberKnife and conventional linac prostate stereotactic body radiation therapy plans: analysis of the pace-B study. Int J Radiat Oncol Biol Phys. 2025, 10.1016\/j.ijrobp.2025.01.014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico AV","year":"1998","unstructured":"D'Amico AV, Whittington R, Malkowicz SB, et al.. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 280:969-74. 10.1001\/jama.280.11.969","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2011.00048","article-title":"Six-dimensional correction of intra-fractional prostate motion with CyberKnife stereotactic body radiation therapy","volume":"1","author":"Lei S","year":"2011","unstructured":"Lei S, Piel N, Oermann EK, et al.. Six-dimensional correction of intra-fractional prostate motion with CyberKnife stereotactic body radiation therapy. Front Oncol. 2011, 1:48. 10.3389\/fonc.2011.00048","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1540482","article-title":"Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer","volume":"15","author":"Gaudian K","year":"2025","unstructured":"Gaudian K, Koh MJ, Koh MJ, et al.. Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer. Front Oncol. 2025, 15:1540482. 10.3389\/fonc.2025.1540482","journal-title":"Front Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01060","article-title":"Stereotactic body radiation therapy (SBRT) for prostate cancer in men with a high baseline International Prostate Symptom Score (IPSS \u2265 15)","volume":"10","author":"Aghdam N","year":"2020","unstructured":"Aghdam N, Pepin A, Buchberger D, et al.. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with a high baseline International Prostate Symptom Score (IPSS \u2265 15). Front Oncol. 2020, 10:1060. 10.3389\/fonc.2020.01060","journal-title":"Front Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-9-52","article-title":"Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer","volume":"9","author":"Bhattasali O","year":"2014","unstructured":"Bhattasali O, Chen LN, Woo J, et al.. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol. 2014, 9:52. 10.1186\/1748-717X-9-52","journal-title":"Radiat Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.01.016","article-title":"Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (Sharp) Consortium: analysis of 344 prospectively treated patients","volume":"110","author":"van Dams R","year":"2021","unstructured":"van Dams R, Jiang NY, Fuller DB, et al.. Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (Sharp) Consortium: analysis of 344 prospectively treated patients. Int J Radiat Oncol Biol Phys. 2021, 110:731-7. 10.1016\/j.ijrobp.2021.01.016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.02.005","article-title":"Local failure after prostate SBRT predominantly occurs in the PI-RADS 4 or 5 dominant intraprostatic lesion","volume":"6","author":"Gorovets D","year":"2023","unstructured":"Gorovets D, Wibmer AG, Moore A, et al.. Local failure after prostate SBRT predominantly occurs in the PI-RADS 4 or 5 dominant intraprostatic lesion. Eur Urol Oncol. 2023, 6:275-81. 10.1016\/j.euo.2022.02.005","journal-title":"Eur Urol Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the flame randomized phase III trial","volume":"39","author":"Kerkmeijer LG","year":"2021","unstructured":"Kerkmeijer LG, Groen VH, Pos FJ, et al.. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the flame randomized phase III trial. J Clin Oncol. 2021, 39:787-96. 10.1200\/JCO.20.02873","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans C","year":"2024","unstructured":"Draulans C, Haustermans K, Pos FJ, et al.. Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial. Radiother Oncol. 2024, 201:110568. 10.1016\/j.radonc.2024.110568","journal-title":"Radiother Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach M","year":"2018","unstructured":"Roach M, Moughan J, Lawton CA, et al.. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018, 19:1504-15. 10.1016\/S1470-2045(18)30528-X","journal-title":"Lancet Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (pop-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy V","year":"2021","unstructured":"Murthy V, Maitre P, Kannan S, et al.. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (pop-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021, 39:1234-42. 10.1200\/JCO.20.03282","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.12.018","article-title":"Pelvic regional control with 25 Gy in 5 fractions in stereotactic radiation therapy for high-risk prostate cancer: pooled prospective outcomes from the sharp consortium","volume":"122","author":"Murthy V","year":"2025","unstructured":"Murthy V, Mallick I, Maitre P, et al.. Pelvic regional control with 25 Gy in 5 fractions in stereotactic radiation therapy for high-risk prostate cancer: pooled prospective outcomes from the sharp consortium. Int J Radiat Oncol Biol Phys. 2025, 122:93-8. 10.1016\/j.ijrobp.2024.12.018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240939","article-title":"Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes","volume":"13","author":"Carrasquilla M","year":"2023","unstructured":"Carrasquilla M, Sholklapper T, Pepin AN, et al.. Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes. Front Oncol. 2023, 13:1240939. 10.3389\/fonc.2023.1240939","journal-title":"Front Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/358859-robotic-stereotactic-body-radiation-therapy-for-high-risk-prostate-cancer-the-georgetown-university-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T22:06:08Z","timestamp":1749679568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/358859-robotic-stereotactic-body-radiation-therapy-for-high-risk-prostate-cancer-the-georgetown-university-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.85798","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}